Cargando…
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establish...
Autores principales: | Rivera Vargas, Thaiz, Apetoh, Lionel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548803/ https://www.ncbi.nlm.nih.gov/pubmed/31191545 http://dx.doi.org/10.3389/fimmu.2019.01181 |
Ejemplares similares
-
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
por: Dosset, Magalie, et al.
Publicado: (2020) -
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018) -
T(H)9 cells in anti-tumor immunity
por: Rivera Vargas, Thaiz, et al.
Publicado: (2016) -
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022) -
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)